Earnings call transcript: Eastman Chemical Q4 2024 beats EPS, stock surges
Eastman Chemical Company (NYSE:EMN) reported its fourth-quarter 2024 earnings, showcasing a strong performance with an EPS of $1.87, surpassing analysts' expectations of $1.61. Despite a slight revenue miss,
Tesla (TSLA) Q4 2024 earnings results miss EPS and revenue expectations
As one of the foremost electric vehicle companies in the world, Tesla continues to be an important company to watch in tech, but its Q4 2024 didn’t bring as good of news as investors might have expected. The company put out its latest earnings results, and with it came a miss on both revenue and earnings-per-share (EPS) versus analyst expectations.
Intel (NASDAQ:INTC) Q4: Beats On Revenue But Quarterly Revenue Guidance Significantly Misses Expectations
Computer processor maker Intel (NASDAQ:INTC) reported Q4 CY2024 results , but sales fell by 7.4% year on year to $14.26 billion. On the other hand, next quarter’s revenue guidance of $12.2 billion was less impressive,
Earnings call transcript: Quest Diagnostics Q4 2024 beats EPS forecast
Following the earnings announcement, Quest Diagnostics (NYSE:DGX)' stock price rose by 0.48% in pre-market trading. The stock's recent movement places it near its 52-week high of $167.08, indicating strong investor confidence.
Intel (INTC) Q4 2024 earnings results beat EPS and revenue expectations
Markets have closed for the day and Intel (INTC) was among the companies that reported its quarterly earnings. The final quarter of Intel’s Q4 saw the tech company beat on both earnings and revenue expectations.
Roper Tops Q4 Revenue, EPS Estimates
Roper Technologies delivered strong fourth-quarter results exceeding market expectations, yet concerns linger about long-term ...
Novartis reports Q4 core EPS $1.98 vs. $1.53 last year
Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...
AbbVie Q4 Earnings: Good 2025 Outlook Despite Enhanced Old And New Headwinds
Analysis of AbbVie Inc.'s Q4 2024 results, 2025 guidance, and future growth prospects, including the impact of clinical trial failures. Click for this ABBV update.
Hess Exceeds Q4 EPS, Revenue Forecasts
Hess reported strong financial performance in its latest earnings release, driven by production increases in key assets ...
Eaton reports Q4 adjusted EPS $2.83, consensus $2.81
Reports Q4 revenue $6.2B, consensus $6.34B. Craig Arnold, Eaton (ETN) chairman and chief executive officer, said, “Once again, we delivered on ...
Roche Q4 Earnings Review: Solid All-Court Performance, But Quiet On GLP-1 Progress
Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...
Dover Delivers Strong Q4 Margins & EPS Beat, Stock Climbs On 2025 Optimism
Dover Corporation reported Q4 results with revenue at $1.930B, up 1% Y/Y but missed consensus. Company expects margin improvement in 2025 with double-digit EPS growth.
Novartis Q4 Core EPS Beats Market, Hikes Dividend; Sees Growth In FY25; Stock Up
Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...